Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
List view / Grid view
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
How to perform successful long term live cell imaging in a high-content analysis system.
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.
Researchers describe how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome...
ELRIG (European Laboratory Research & Innovation Group) has announced its first Discovery Technologies meeting, which will take place at Alderley Park, located near Macclesfield in Cheshire.
The FoxM1 gene will drive the development of new drugs to reverse a process called vascular remodelling - a key feature in pulmonary hypertension...
27 April 2018 | By Mitra Biotech
In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
27 April 2018 | By TECAN
ABOUT THIS WEBINAR: In this two-part webinar, both automation of P450 (CYP) assays and the automatisation of cellular differentiation processes and compound testing using human induced pluripotent stem cells based assays was covered. Metabolism of drugs is a key factor in compound toxicity, and automated assays which monitor inhibition or…
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.